Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by BidaskClub

BidaskClub lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a strong sell rating in a report published on Tuesday morning, BidAskClub reports.

ENTA has been the topic of a number of other reports. Zacks Investment Research cut Enanta Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, August 12th. Wolfe Research began coverage on Enanta Pharmaceuticals in a research report on Friday, May 24th. They set an outperform rating and a $117.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Enanta Pharmaceuticals has an average rating of Hold and a consensus price target of $104.75.

NASDAQ ENTA traded up $0.01 during trading on Tuesday, hitting $69.41. The company’s stock had a trading volume of 8,372 shares, compared to its average volume of 176,976. The firm has a 50 day moving average price of $71.98 and a 200 day moving average price of $86.58. The firm has a market cap of $1.36 billion, a P/E ratio of 19.80 and a beta of 0.97. Enanta Pharmaceuticals has a 52 week low of $63.37 and a 52 week high of $106.80.



Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.27. The business had revenue of $44.40 million for the quarter, compared to analysts’ expectations of $46.98 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. Enanta Pharmaceuticals’s quarterly revenue was down 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.97 earnings per share. As a group, analysts predict that Enanta Pharmaceuticals will post 2.47 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in ENTA. Marshall Wace North America L.P. boosted its stake in Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after buying an additional 207,326 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at $16,686,000. Price T Rowe Associates Inc. MD boosted its stake in Enanta Pharmaceuticals by 11.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,528,541 shares of the biotechnology company’s stock valued at $128,978,000 after buying an additional 159,504 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Enanta Pharmaceuticals by 8.1% in the 2nd quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock valued at $79,721,000 after buying an additional 70,390 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in Enanta Pharmaceuticals by 1,189.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 69,102 shares of the biotechnology company’s stock valued at $5,831,000 after buying an additional 63,742 shares in the last quarter. 88.79% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: FAANG Stocks

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.